Cited by 120Viral-associated cancers and disordersLymphoma Diagnosis and TreatmentCNS Lymphoma Diagnosis and Treatment

The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.

Comprehensive Transcriptome and Mutational Profiling of Endemic Burkitt Lymphoma Reveals EBV Type–Specific Differences

Open access
Kaymaz, Yasin, Oduor, Cliff I., Yu, Hongbo, Otieno, Juliana A., Ong'echa, John Michael, Moormann, Ann M., Bailey, Jeffrey A.·2017·Molecular Cancer Research

Published version of a preprint

Abstract

Endemic Burkitt lymphoma (eBL) is the most common pediatric cancer in malaria-endemic equatorial Africa and nearly always contains Epstein–Barr virus (EBV), unlike sporadic Burkitt lymphoma (sBL) that occurs with a lower incidence in developed countries. Given these differences and the variable clinical presentation and outcomes, we sought to further understand pathogenesis by investigating transcriptomes using RNA sequencing (RNAseq) from multiple primary eBL tumors compared with sBL tumors. Within eBL tumors, minimal expression differences were found based on: anatomical presentation site, in-hospital survival rates, and EBV genome type, suggesting that eBL tumors are homogeneous without marked subtypes. The outstanding difference detected using surrogate variable analysis was the significantly decreased expression of key genes in the immunoproteasome complex (PSMB9/β1i, PSMB10/β2i, PSMB8/β5i, and PSME2/PA28β) in eBL tumors carrying type 2 EBV compared with type 1 EBV. Second, in comparison with previously published pediatric sBL specimens, the majority of the expression and pathway differences was related to the PTEN/PI3K/mTOR signaling pathway and was correlated most strongly with EBV status rather than geographic designation. Third, common mutations were observed significantly less frequently in eBL tumors harboring EBV type 1, with mutation frequencies similar between tumors with EBV type 2 and without EBV. In addition to the previously reported genes, a set of new genes mutated in BL, including TFAP4, MSH6, PRRC2C, BCL7A, FOXO1, PLCG2, PRKDC, RAD50, and RPRD2, were identified. Overall, these data establish that EBV, particularly EBV type 1, supports BL oncogenesis, alleviating the need for certain driver mutations in the human genome. Implications: Genomic and mutational analyses of Burkitt lymphoma tumors identify key differences based on viral content and clinical outcomes suggesting new avenues for the development of prognostic molecular biomarkers and therapeutic interventions. Mol Cancer Res; 15(5); 563–76. ©2017 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1541-7786.mcr-16-0305

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 65 references

Cited by

Sorted by citations

See all 120

Metadata

Authors
Kaymaz, Y., Oduor, C. I., Yu, H., Otieno, J. A., Ong'echa, J. M., Moormann, A. M., & Bailey, J. A.
Affiliations
  • University of Massachusetts Chan Medical School (US)
  • Maseno University (KE)
  • Ministry of Health (KE)
  • 2Center for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya.
Corresponding author
Bailey, Jeffrey A.
Venue
Molecular Cancer Research
Published
2017-05-01
Volume
15
Issue
5
Pages
563-576
ISSN
  • 1541-7786 (ISSN-L)
  • 1557-3125
OpenAlex
W2580872164
Cited by
120
References
65
Citations by year
2026: 10 · 2025: 11 · 2024: 17 · 2023: 23 · 2022: 16 · 2021: 14 · 2020: 11 · 2019: 9 · 2018: 4 · 2017: 5
FWCI
3.50
Type
journal article
Language
en
Open access
Locations
  • Molecular Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • The Journal of the American Medical Association (JAMA) Network (American Medical Association) (submittedVersion)
Funders
  • National Institutes of Health (UL1TR001453, UL1TR000161)
  • National Cancer Institute (R01CA134051, R01CA189806)
  • National Institute of Allergy and Infectious Diseases (R01AI099473)
  • National Center for Advancing Translational Sciences
Topics
  • Health Sciences › Medicine › Oncology › Viral-associated cancers and disorders
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
  • Health Sciences › Medicine › Clinical Neurology › CNS Lymphoma Diagnosis and Treatment
Keywords
endemic Burkitt lymphoma, sporadic Burkitt lymphoma, Epstein-Barr virus, transcriptome, mutational profiling, immunoproteasome, PSMB9, TFAP4, MSH6, prognostic factors, pediatric lymphoma
MeSH terms
Adolescent, Burkitt Lymphoma, Child, Child, Preschool, Herpesvirus 4, Human, Female, Humans, Kenya, Male, Mutation, Genome, Viral, Sequence Analysis, RNA, Endemic Diseases, Epstein-Barr Virus Infections, Gene Expression Profiling, Gene Regulatory Networks, Mutation Rate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review